Endogenex Closes $50 Million Series C

Endogenex closed a $50 million Series C extension, endogenex announced the closing of a $50 million extension of its Series C financing.

Arboretum Ventures joined as lead investor, arboretum Ventures joined as a new lead investor in the financing.

Endogenex will use proceeds to complete the ReCET Clinical Study, proceeds will fund completion of the company's pivotal ReCET Clinical Study.

Will use proceeds to support FDA regulatory pathway, proceeds will support the company's regulatory path to FDA approval.

Total Series C financing reached $138 million, the $50 million extension adds to a prior $88 million Series C from June 2024, totaling $138 million.